Skip to content

BobcatBio

3 viewers · 30d

Total raised

$5.3M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $5.3M
ROUNDS
1
INVESTORS
11
FOUNDED
2020
HQ
Hummelstown, PA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

BobcatBio, Inc. is an innovative biotechnology company dedicated to developing advanced cancer therapies that specifically target malignant cells while protecting healthy tissue. Focused on harnessing cutting-edge immunotherapeutic techniques, the company is committed to revolutionizing cancer treatment by creating more effective and less toxic options for patients.

What sets it apart

BobcatBio stands out for its approach in utilizing cancer-specific T cell therapies, which represent a novel direction in oncology, aiming for targeted elimination of cancer cells.

Funding history

1 round
Equity+2Feb 26, 2025
Form D
+$5.3M$5.3M total

Latest SEC filings

via EDGAR · CIK 0001876657
Form D · Feb 26, 2025View on EDGAR

Products

1 tracked

Cancer-Specific T Cell Therapies

Immunotherapy

BobcatBio's flagship product line consists of advanced cancer-specific T cell therapies that are engineered to selectively target cancer cells. These therapies are designed to enhance the immune system's ability to recognize and destroy malignancies while minimizing harm to normal, healthy tissues.

  • Targeted action against cancer cells
  • Reduced toxicity compared to traditional therapies
  • Potential for application across multiple cancer types
  • Innovative design leveraging the body's own immune response

Links

WebsiteSEC EDGAR filings